Status:
RECRUITING
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
Lead Sponsor:
Endeavor Health
Collaborating Sponsors:
Northwestern University
Johns Hopkins University
Conditions:
Prostate Cancer
Eligibility:
MALE
40-69 years
Brief Summary
Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment
Detailed Description
Inherited genetic changes, including rare pathogenic mutations (RPMs) in several major genes and single nucleotide polymorphisms (SNPs)-based genetic risk scores (GRS) have been consistently associate...
Eligibility Criteria
Inclusion
- Consecutive patients undergoing prostate biopsy for detection of prostate cancer
- Aged 40 to 69 years
- Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos)
- PSA between 2.5-10 ng/mL
Exclusion
- Previous diagnosis of prostate cancer.
- Ethnicity outside the inclusion criterion (including mixed ethnicity).
- Any prior PSA test result outside the range of inclusion criterion.
Key Trial Info
Start Date :
December 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 13 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05295407
Start Date
December 13 2021
End Date
December 13 2025
Last Update
March 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NorthShore University HealthSystem
Evanston, Illinois, United States, 60626